Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finkel

Showing results (151-160 of 289) with videos related to

Pageof 29
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 4, 2011
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe diseaseSuhrad G Banugaria, Sean N Prater, Yiu-Ki Ng, et al.
Journal of the Peripheral Nervous System : JPNS|February 7, 2023
Validation of the parent-proxy pediatric Charcot-Marie-Tooth disease quality of life outcome measureTong Tong Wu, Richard S Finkel, Carly E Siskind, et al.
Journal of the Peripheral Nervous System : JPNS|September 18, 2025
Designing and Implementing a Web-Based Platform for Accurate and Reliable Clinical Outcome Measures and Global Certification for Evaluating Charcot-Marie-Tooth diseaseKayla M D Cornett, Tim Estilow, Paula Bray, et al.
Plos One|December 19, 2013
Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophyRichard S Finkel, Kevin M Flanigan, Brenda Wong, et al.
Journal of Neuromuscular Diseases|November 11, 2025
Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registryYasemin Erbaş, Laurent Servais, Perry B Shieh, et al.
Med (New York, N.Y.)|March 11, 2023
Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophinSvetlana Gorokhova, Joachim Schessl, Yaqun Zou, et al.
Drug Safety|August 12, 2021
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec TherapyJohn W Day, Jerry R Mendell, Eugenio Mercuri, et al.
JAMA|February 5, 1998
Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart diseaseS P Roose, F Laghrissi-Thode, J S Kennedy, et al.
Journal of the Peripheral Nervous System : JPNS|May 11, 2023
Validation of the parent-proxy version of the pediatric Charcot-Marie-Tooth disease quality of life instrument for children aged 0-7 yearsTong Tong Wu, Richard S Finkel, Carly E Siskind, et al.
Molecular Genetics and Metabolism|November 20, 2012
Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidaseTyler Mark Pierson, Paola A Torres, Bei-Jin Zeng, et al.
Pageof 29

Showing results (151-160 of 289) with videos related to

Sort By:
Pageof 29
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 4, 2011
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe diseaseSuhrad G Banugaria, Sean N Prater, Yiu-Ki Ng, et al.
Journal of the Peripheral Nervous System : JPNS|February 7, 2023
Validation of the parent-proxy pediatric Charcot-Marie-Tooth disease quality of life outcome measureTong Tong Wu, Richard S Finkel, Carly E Siskind, et al.
Journal of the Peripheral Nervous System : JPNS|September 18, 2025
Designing and Implementing a Web-Based Platform for Accurate and Reliable Clinical Outcome Measures and Global Certification for Evaluating Charcot-Marie-Tooth diseaseKayla M D Cornett, Tim Estilow, Paula Bray, et al.
Plos One|December 19, 2013
Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophyRichard S Finkel, Kevin M Flanigan, Brenda Wong, et al.
Journal of Neuromuscular Diseases|November 11, 2025
Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registryYasemin Erbaş, Laurent Servais, Perry B Shieh, et al.
Med (New York, N.Y.)|March 11, 2023
Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophinSvetlana Gorokhova, Joachim Schessl, Yaqun Zou, et al.
Drug Safety|August 12, 2021
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec TherapyJohn W Day, Jerry R Mendell, Eugenio Mercuri, et al.
JAMA|February 5, 1998
Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart diseaseS P Roose, F Laghrissi-Thode, J S Kennedy, et al.
Journal of the Peripheral Nervous System : JPNS|May 11, 2023
Validation of the parent-proxy version of the pediatric Charcot-Marie-Tooth disease quality of life instrument for children aged 0-7 yearsTong Tong Wu, Richard S Finkel, Carly E Siskind, et al.
Molecular Genetics and Metabolism|November 20, 2012
Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidaseTyler Mark Pierson, Paola A Torres, Bei-Jin Zeng, et al.
Pageof 29